The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1398
Citalopram (Celexa) and QT Interval Prolongation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Citalopram (Celexa) and QT Interval Prolongation
The FDA has asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) antidepressant citalopram (Celexa, and others) to revise the labeling of the drug to include new warnings about the risk of QT interval prolongation.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Citalopram (Celexa) and QT Interval Prolongation
Article code: 1398b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.